SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Higa, G. M
Right arrow Articles by Landreth, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Higa, G. M
Right arrow Articles by Landreth, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy

Gerald M Higa, PharmD

Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; School of Pharmacy, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgan-town, WV, USA; WVU School of Pharmacy, Robert C. Byrd Health Sciences Center, PO Box 9520, West Virginia University, Morgantown, WV 26506-9520, USA ghiga{at}hsc.wvu.edu

Miklos L Auber, MD

Ramin Altaha, MD

Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgan-town, WV, USA

Debbie Piktel, BS

Department of Immunology and Microbiology, West Virginia University, Morgantown, WV, USA

Sohba Kurian, MD

Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV, USA; Department of Medicine, Section of Hematology-Oncology, West Virginia University, Morgantown, WV, USA

Gerry Hobbs, PhD

Department of Community Medicine, West Virginia University, Morgantown, WV, USA

Kenneth Landreth, PhD

Department of Immunology and Microbiology, West Virginia University, Morgantown, WV, USA

Background. Even though direct cause and effect has not been proved, clinical evidence suggests serotonin and substance P (SP) are involved in the emetic response following chemotherapy. Because of several parallels, we hypothesized that SP release, like serotonin, may be propagated by chemotherapy and both substances can be measured in biological fluids, and correlated with a particular phase of emesis.

Methods. Urinary 5-hydroxyindoleacetic acid (5-HIAA) was assessed by HPLC; serum and urine SP were measured by immunoassay. In addition to construction of neurotransmitter profiles, all SP data were grouped according to cisplatin dosages, = or>75 mg/m 2 versus <75 mg/m2, and phase of emesis, acute versus delayed. Analyses of these data were performed by repeated measures analysis of variance.

Results. Samples were collected over a 72-hour period from 26 adult patients who received cisplatin-(n=13) or non-cisplatin-containing (n=13) chemotherapy. Mean baseline 5-HIAA: creatinine ratios were 5.23 and 5.16 in females and males, respectively; mean baseline SP levels were 392 and 181 pg/mL in females and males, respectively. Comparisons between SP data stratified by cisplatin dosage and emetic phase were significantly different, P <0.0001.

Conclusions. Laboratory studies provide additional evidence that serotonin and SP are involved primarily, though not exclusively, in acute and delayed vomiting, respectively.

Key Words: substance P • 5-HIAA • NK1 receptor • 5-HT3 receptor

Journal of Oncology Pharmacy Practice, Vol. 12, No. 4, 201-209 (2006)
DOI: 10.1177/1078155206072080


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. C. De Jonghe and C. C. Horn
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus)
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2009; 296(4): R902 - R911.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. C. De Jonghe and C. C. Horn
Chemotherapy-induced pica and anorexia are reduced by common hepatic branch vagotomy in the rat
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R756 - R765.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
P. Hartvig
Letter to the editor
Journal of Oncology Pharmacy Practice, March 1, 2007; 13(1): 57 - 58.
[PDF]



Advertisement